Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
21 Dezember 2023 - 3:00PM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced that it has entered into a common stock
purchase agreement with Baillie Gifford on behalf of accounts that
it manages for the sale of 3,387,446 shares of its common stock in
a registered direct offering at an offering price of $26.77 per
share.
Gross proceeds are approximately $90.7 million, before deducting
expenses payable by Guardant Health. Guardant Health intends to use
the net proceeds from the offering primarily for general corporate
purposes, including working capital, operating expenses and capital
expenditures.
"We are proud to be supported by Baillie Gifford,” said Helmy
Eltoukhy, co-founder and co-CEO of Guardant Health. “At Guardant,
we are driven by the impact our products have on patient outcomes
each and every day, and look forward to Baillie Gifford’s continued
support as we work to serve many more patients with our growing
product portfolio.”
“We have deep conviction in Guardant’s ability to execute on the
opportunity ahead,” said Brogan Harris at Baillie Gifford. “We look
forward to a long-term partnership with Guardant’s team, as they
work to continue to improve outcomes and transform patient lives
across the continuum of care.”
The shares of common stock are being offered by Guardant Health
pursuant to an automatic shelf registration statement on Form S-3
that was previously filed with the U.S. Securities and Exchange
Commission, or the SEC, and automatically became effective upon
filing. A final prospectus supplement and accompanying prospectus
relating to and describing the terms of the offering will be filed
with the SEC and is available on the SEC’s website at
www.sec.gov.
Electronic copies of the final prospectus supplement and
accompanying prospectus may be obtained when available, on the
SEC’s website at http://www.sec.gov or by contacting Guardant
Investor Relations, 3100 Hanover Street, Palo Alto, California
94304, by email: investors@guardanthealth.com or by telephone:
(657) 254-5417.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction.
About Guardant Health
Guardant Health is a leading precision medicine company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
relating to Guardant Health’s future results, reaching more
patients with a growing product portfolio, or regarding the
potential benefits and advantages of Guardant Health’s platforms,
assays and tests, which involve risks and uncertainties that could
cause Guardant Health’s actual results to differ materially from
the anticipated results and expectations expressed in these
forward-looking statements. These statements are based on current
expectations, forecasts and assumptions, and actual outcomes and
results could differ materially from these statements due to a
number of factors. These and additional risks and uncertainties
that could affect Guardant Health’s financial and operating results
and cause actual results to differ materially from those indicated
by the forward-looking statements made in this press release
include those discussed under the captions “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operation” and elsewhere in its Annual Report on Form
10-K for the year ended December 31, 2022, and any current and
periodic reports filed with or furnished to the Securities and
Exchange Commission thereafter. The forward-looking statements in
this press release are based on information available to Guardant
Health as of the date hereof, and Guardant Health disclaims any
obligation to update any forward-looking statements provided to
reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is based,
except as required by law. These forward-looking statements should
not be relied upon as representing Guardant Health’s views as of
any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231221301429/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Melissa Marasco press@guardanthealth.com
+1 650-647-3711
Guardant Health (NASDAQ:GH)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
Von Mai 2023 bis Mai 2024